Additional file 1: of Front-line intraperitoneal versus intravenous chemotherapy in stage III-IV epithelial ovarian, tubal, and peritoneal cancer with minimal residual disease: a competing risk analysis

Yen Hou Chang (Creator)
Wai-Hou Li (Contributor)
Yi Chang (Creator)
Chia-Wen Peng (Creator)
Ching-Hsuan Cheng (Contributor)
Wei Pin Chang (Creator)
Chi Mu Chuang (Contributor)

Dataset

Description

Dataset for computing competing risks. (CSV 18Â kb)

Date made available	2016
Publisher	Figshare

DOI
10.6084/m9.figshare.c.3642380_d1.v1

Access Dataset

CC BY + CC0

1 Article

Front-line intraperitoneal versus intravenous chemotherapy in stage III-IV epithelial ovarian, tubal, and peritoneal cancer with minimal residual disease: a competing risk analysis
Chang, Y.-H., Li, W.-H., Chang, Y., Peng, C.-W., Cheng, C.-H., Chang, W. P. & Chuang, C.-M., 2016, In: BMC Cancer. 16, 1, p. 1-8 8 p.
Research output: Contribution to journal › Article › peer-review
5 Citations (Scopus)

Cite this

Chang, Y. (Creator), Li, W. (Contributor), Chang, Y. (Creator), Peng, C. (Creator), Cheng, C. (Contributor), Chang, W. (Creator), Chuang, C. (Contributor) (2016). Additional file 1: of Front-line intraperitoneal versus intravenous chemotherapy in stage III-IV epithelial ovarian, tubal, and peritoneal cancer with minimal residual disease: a competing risk analysis. Figshare. 10.6084/m9.figshare.c.3642380_d1.v1

Additional file 1: of Front-line intraperitoneal versus intravenous chemotherapy in stage III-IV epithelial ovarian, tubal, and peritoneal cancer with minimal residual disease: a competing risk analysis

Description

DOI

Access Dataset

Research output

Front-line intraperitoneal versus intravenous chemotherapy in stage III-IV epithelial ovarian, tubal, and peritoneal cancer with minimal residual disease: a competing risk analysis

Cite this